Barclays Issues Positive Forecast for Intuitive Surgical (NASDAQ:ISRG) Stock Price

Intuitive Surgical (NASDAQ:ISRG) had its target price upped by analysts at Barclays from $610.00 to $674.00 in a research report issued on Monday. Barclays‘s price target indicates a potential upside of 17.39% from the stock’s previous close.

Other analysts also recently issued reports about the company. Citigroup lifted their price target on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $522.00 to $650.00 in a research note on Monday, December 2nd. Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Finally, Piper Sandler reissued an “overweight” rating and set a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Stock Up 0.1 %

Shares of NASDAQ:ISRG opened at $574.14 on Monday. The company has a 50-day moving average price of $548.00 and a 200 day moving average price of $506.12. Intuitive Surgical has a 52 week low of $364.17 and a 52 week high of $616.00. The company has a market cap of $204.50 billion, a P/E ratio of 92.31, a PEG ratio of 5.19 and a beta of 1.39.

Insider Buying and Selling

In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,967,734. This trade represents a 6.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jamie Samath sold 22,903 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the transaction, the insider now owns 8,757 shares of the company’s stock, valued at approximately $4,597,425. This trade represents a 72.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,749 shares of company stock valued at $15,303,875. Insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds have recently bought and sold shares of the company. Berbice Capital Management LLC bought a new position in Intuitive Surgical during the fourth quarter worth $26,000. Godsey & Gibb Inc. lifted its holdings in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares during the last quarter. MidAtlantic Capital Management Inc. bought a new position in Intuitive Surgical during the 3rd quarter worth $33,000. Decker Retirement Planning Inc. bought a new stake in Intuitive Surgical in the fourth quarter valued at $36,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Intuitive Surgical in the 3rd quarter worth about $38,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.